The Priority Review

Clinical trials Brief

Nektar posts results of Phase 2/3 NKTR-255 trial in relapsed/refractory large B-cell lymphoma

Results for the study were first posted on ClinicalTrials.gov on October 16, 2026. The terminated study enrolled 15 participants and had a primary completion date of May 22, 2024.

Primary source

ClinicalTrials.gov results record, October 16, 2026

NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

Read the source clinicaltrials.gov

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation